Profound Medical Corp. announced changes to its management team and structure designed to further position the Company for continued sales success and global growth. Abbey Goodman and Hartmut Warnken have been appointed Chief Commercial Officer – U.S. and Chief Commercial Officer – OUS, respectively, with each having overall responsibility for leading Profound's commercial strategy, sales, sales operations, and marketing activities in their corresponding geographies.

They succeed Kenneth Knudson, who is leaving the Company. Ms. Goodman brings over 17 years of medical device sales experience, most recently serving as Profound's VP, U.S. Sales & Marketing. Prior to joining the Company in June 2019, she progressed through a variety of senior sales leadership roles with Hologic Inc., Novadaq Technologies Inc., Covidien Plc (now Medtronic plc), and DePuy Mitek Inc. Ms. Goodman earned a BS in Biological Engineering from Louisiana State University.

Mr. Warnken has over 20 years of experience in the medical technology industry. Before joining Profound in November 2015 as VP, International Sales & Marketing, he served as VP & General Manager Europe, Middle East, Japan and Asia Pacific, Managing Director/Officer for IMRIS Pte. Ltd., IMRIS Germany GmbH and IMRIS KK Japan.

Prior to IMRIS, Mr. Warnken held two positions at BrainLAB AG. He holds an MBA from ESCP-Europe Business School. Profound also announced that Michael Mydra, who leads Profound's reimbursement activities as VP, Head of Global Market Access, will now report directly to Dr. Menawat.